Analysts expect NRx Pharmaceuticals to post earnings of ($0.30) per share for the quarter. NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Friday, March 14th.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports.

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

Additionally on Monday, NRx Pharmaceuticals (NRXP) reported a FY24 loss per share of ($2.36), which compared to a loss per share of ($3.98) for the same period last year. As of December 31 ...

NRX-100 (IV, preservative-free ketamine)According to the CDC, more than 13 million adults contemplate suicide each year; NRX-100 – IV ketamine for Suicidal Depression - can help address this ...

As of 2:04:45 pm GMT-4. Market open. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results ...

The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by D. Boral Capital on March 24, 2025. The analyst firm set a price target for $31.00 expecting NRXP to rise to within 12 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

At close: March 28 at 4:00:00 PM EDT ...